AbbVieABBV

About AbbVie

AbbVie Inc. is a research-based biopharmaceutical company that develops and commercializes prescription drugs for immunology, oncology, neuroscience, eye care, and aesthetics. Immunology is the largest franchise, anchored historically by Humira (adalimumab) and now increasingly by the successor therapies Skyrizi and Rinvoq, which the company has positioned to absorb Humira's revenue as biosimilar competition erodes it. Oncology contributions come primarily from Imbruvica and Venclexta, while neuroscience includes Vraylar, Botox Therapeutic, and migraine treatments Ubrelvy and Qulipta. Aesthetics, acquired with Allergan, is centered on Botox Cosmetic and Juvederm dermal fillers. Immunology typically drives the bulk of profit, with the Skyrizi and Rinvoq pairing serving as the company's stated long-term growth engine.

Serious holders track the pace of Humira erosion against Skyrizi and Rinvoq uptake, since concentration risk in immunology has been the defining structural question for the company. Pipeline productivity, patent cliffs on major assets, and the durability of Botox in a competitive aesthetics market are watched closely, as is exposure to U.S. drug-pricing legislation, including Medicare price negotiation under the Inflation Reduction Act. Investors also monitor leverage carried from the Allergan acquisition, the pace of deleveraging, dividend policy as a Dividend Aristocrat lineage inherited from Abbott, and payer dynamics with pharmacy benefit managers. Regulatory exposure spans the FDA, EMA, and reimbursement authorities across major markets.

AbbVie was formed on January 1, 2013, through the spin-off of Abbott Laboratories' research-based pharmaceutical business, with headquarters in North Chicago, Illinois. Abbott had built the underlying franchise substantially through its 2001 acquisition of Knoll Pharmaceuticals from BASF, which brought adalimumab into the portfolio. As an independent company, AbbVie pursued external growth through the acquisitions of Pharmacyclics in 2015, which added Imbruvica, and Stemcentrx the following year. Its transformational transaction was the roughly $63 billion acquisition of Allergan plc, completed in May 2020, which added aesthetics, eye care, and neuroscience assets and reshaped the company into a more diversified specialty pharmaceutical group.

Revenue is generated by selling branded prescription medicines and aesthetic products to wholesalers, specialty distributors, hospitals, retail pharmacies, government purchasers, and, in aesthetics, directly to physicians and clinics. In the United States, net pricing is shaped by rebate negotiations with pharmacy benefit managers and managed-care organizations that determine formulary placement, while international sales flow through national health systems and tender processes. Competitive position rests on patent protection, clinical differentiation, and physician relationships, with principal rivals including Johnson & Johnson, Bristol-Myers Squibb, Merck, Pfizer, Roche, Novartis, Eli Lilly, and Amgen across therapeutic areas. The United States accounts for the majority of revenue, with international sales providing a meaningful but smaller contribution.

Company profile by LineVest editorial. Journalism, not investment advice.